SOTA’s Dental Imaging Software Gets Pearl’s AI Pathology Detection Capabilities

Pearl and SOTA have partnered to offer native support for Pearl’s industry-leading, FDA-cleared radiologic AI solution Second Opinion® within the SOTA Cloud® software platform. SOTA Cloud® will be the first dental imaging software in the United States to offer a fully-integrated clinical AI feature set.

Pearl, the global leader in dental AI solutions, and SOTA Imaging, the leading manufacturer of dental imaging hardware and software, announced today a partnership to integrate Pearl’s FDA-cleared Second Opinion® real-time clinical pathology detection artificial intelligence (AI) solution with SOTA’s popular SOTA Cloud® dental imaging software.

Native support for Pearl’s chairside AI within SOTA’s cloud-based imaging interface means that, for the first time, dentists in the United States can conveniently capture, display, and perform AI-assisted clinical evaluation of dental radiographs within a single software platform.

“Together with SOTA, we are pushing the envelope of dental imaging further toward a fully AI-powered dental future,” said Ophir Tanz, Pearl’s founder and CEO. “AI will be a basic utility in dentistry and we see obvious advantages to making that utility an integral feature of the tools that dentists are already using. Through this partnership, dentists using SOTA Cloud® can seamlessly access Pearl’s AI capabilities to obtain better, more consistent insights from patient imagery and present cases to patients more effectively –– leading to better outcomes, a higher standard of care and more productive patient communication.”

Pearl’s Second Opinion® is a clinical AI system cleared for use as a patient-facing radiologic aid to dentists in over 90 countries. With native Second Opinion® integration, dental practices using SOTA Cloud® –– the robust cloud-based dental imaging software which SOTA introduced last year to complement its line of state-of-the-art intraoral cameras and X-ray image sensors –– can view automatic AI detections of most conditions commonly found in dental X-rays.

“Understanding the needs of clinicians and ensuring that dentists are able to focus solely on providing the best possible patient care has always been the top priority when developing our software,” said SOTA founder and president Brian Kim. “Our partnership with Pearl speaks directly to that focus by giving practices using SOTA Cloud® push-button access to the most innovative AI technology available for streamlined patient communication and improved image-based diagnostic evaluations.”

To register for SOTA Cloud® with fully-integrated AI capabilities, visit: https://info.sotaimaging.com/sotaxpearlpartnership

To learn more about Pearl’s Second Opinion®, visit: www.hellopearl.com/products/second-opinion.

To learn more about SOTA Cloud®, visit: www.sotaimaging.com/sota-cloud

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”